Gregory R Jackson1, Mark E Clark, Ingrid U Scott, Laura E Walter, David A Quillen, Mitchell G Brigell. 1. *PhD †BS ‡MD, MPH §COA ∥MD Penn State Hershey Eye Center, Penn State College of Medicine, Hershey, Pennsylvania (GRJ, IUS, LEW, DAQ); Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama (MEC); and Translational Medicine, Novartis Institute for BioMedical Research, Cambridge, Massachusetts (MGB).
Abstract
PURPOSE: A sensitive endpoint is required for clinical trials evaluating preventative therapies for early age-related macular degeneration (AMD). Dark adaptation (DA) is a sensitive marker of AMD and has been proposed as a potential endpoint. This study evaluated whether significant changes in DA speed could be detected in participants with early to intermediate AMD at 12 months following baseline DA measurement. METHODS: Dark adaptation, visual acuity (VA), and fundus photography were obtained at baseline and at 6 and 12 months in 26 subjects with AMD and in 6 subjects with normal retinal health. Disease severity was assessed by the Nine-Step Age-Related Eye Disease Study AMD severity scale. RESULTS: At 12 months, significant progression of DA impairment occurred in 5 of 26 (19%) participants with AMD. None of the participants with AMD exhibited a significant worsening of fundus grade or decrease of acuity related to disease progression. The normal group exhibited stable DA and VA during the observation period. CONCLUSIONS: Significant worsening of DA was observed in 19% of subjects with AMD in 12 months of observation, despite stable VA and fundus appearance. This study suggests that DA may be a suitable functional endpoint for early clinical studies evaluating novel treatments for early to intermediate AMD.
PURPOSE: A sensitive endpoint is required for clinical trials evaluating preventative therapies for early age-related macular degeneration (AMD). Dark adaptation (DA) is a sensitive marker of AMD and has been proposed as a potential endpoint. This study evaluated whether significant changes in DA speed could be detected in participants with early to intermediate AMD at 12 months following baseline DA measurement. METHODS: Dark adaptation, visual acuity (VA), and fundus photography were obtained at baseline and at 6 and 12 months in 26 subjects with AMD and in 6 subjects with normal retinal health. Disease severity was assessed by the Nine-Step Age-Related Eye Disease Study AMD severity scale. RESULTS: At 12 months, significant progression of DA impairment occurred in 5 of 26 (19%) participants with AMD. None of the participants with AMD exhibited a significant worsening of fundus grade or decrease of acuity related to disease progression. The normal group exhibited stable DA and VA during the observation period. CONCLUSIONS: Significant worsening of DA was observed in 19% of subjects with AMD in 12 months of observation, despite stable VA and fundus appearance. This study suggests that DA may be a suitable functional endpoint for early clinical studies evaluating novel treatments for early to intermediate AMD.
Authors: Cynthia Owsley; Carrie Huisingh; Gregory R Jackson; Christine A Curcio; Alexander J Szalai; Nassrin Dashti; Mark Clark; Kia Rookard; Mark A McCrory; Tyler T Wright; Michael A Callahan; Lanning B Kline; C Douglas Witherspoon; Gerald McGwin Journal: Invest Ophthalmol Vis Sci Date: 2014-05-22 Impact factor: 4.799
Authors: Jan H Terheyden; Robert P Finger; Steffen Schmitz-Valckenberg; Hansjürgen Agostini; Claudia Dahlke; Laura Kuehlewein; Gabriele E Lang; Daniel Pauleikhoff; Armin Wolf; Michael K Boettger; Ulrich F O Luhmann; Friedrich Asmus; Frank G Holz Journal: Ophthalmologe Date: 2019-12 Impact factor: 1.059
Authors: Arthika Chandramohan; Sandra S Stinnett; John T Petrowski; Stefanie G Schuman; Cynthia A Toth; Scott W Cousins; Eleonora M Lad Journal: Retina Date: 2016-05 Impact factor: 4.256
Authors: Brett G Jeffrey; Oliver J Flynn; Laryssa A Huryn; Maximilian Pfau; Catherine A Cukras Journal: Invest Ophthalmol Vis Sci Date: 2022-06-01 Impact factor: 4.925
Authors: Monica B Sevilla; Gerald McGwin; Eleonora M Lad; Mark Clark; Eric L Yuan; Sina Farsiu; Christine A Curcio; Cynthia Owsley; Cynthia A Toth Journal: Am J Ophthalmol Date: 2016-03-03 Impact factor: 5.258
Authors: Cynthia Owsley; Gerald McGwin; Mark E Clark; Gregory R Jackson; Michael A Callahan; Lanning B Kline; C Douglas Witherspoon; Christine A Curcio Journal: Ophthalmology Date: 2015-10-30 Impact factor: 12.079